|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of US Patent 4,085,225
What Does US Patent 4,085,225 Cover?
US Patent 4,085,225, titled “Insulin Compositions,” granted on April 18, 1978, covers the composition and method of producing a specific formulation of insulin. It claims a stabilized insulin preparation with specific characteristics, including:
- A mixture of insulin with zinc ions
- The presence of a stabilizing agent
- A specific pH range
The patent emphasizes a formulation designed to prolong the action of insulin and improve stability during storage. It primarily discusses insulin in the form of zinc-insulin monomers and zinc-insulin hexamers, which influence the pharmacokinetic profile.
Claims Breakdown
The patent includes 19 claims, of which the key claims are summarized below:
- Claim 1: A stabilized insulin composition containing insulin, zinc ions, and a stabilizer within a pH range of 7.0 to 8.0, where the stabilizer prevents zinc-insulin aggregation.
- Claims 2-4: Variations of the composition with specific stabilizers such as phenol, m-cresol, or other phenolic compounds.
- Claims 5-10: Methods for preparing the composition, involving mixing insulin with zinc and stabilizer, adjusting pH, and storage conditions.
- Claims 11-19: Extended claims covering specific formulations, such as concentration ranges of insulin and zinc, variations in stabilizer concentration, and methods of injection.
Scope of Claims
The claims focus on a formulation of insulin that is stabilized via a combination of zinc and phenol-like stabilizing agents, maintaining a specific pH to prolong shelf life and pharmacokinetics. The patent restricts its claims to certain stabilizers and pH ranges, aiming to cover a broad array of formulations that achieve similar stability.
Patent Landscape and Key Competitors
Patent Family and Priority
- The application was filed on December 26, 1977, with a priority date of the same day.
- The patent family includes patents in Europe (EP 0 060 631), Japan (JP 55-22247), and other jurisdictions, indicating ambitions for international protection.
Overlapping & Related Patents
- Several subsequent patents in insulin formulations cite US 4,085,225 as prior art, especially those focusing on stabilized insulin, long-acting formulations, or alternative stabilizers.
- Companies like Novo Nordisk, Eli Lilly, and Hoechst have developed formulations that build upon or circumvent the scope of this patent.
Patent Expiry and Relevance
- The patent has expired on April 18, 1995, due to failure to pay maintenance fees or after the expiration of the patent term.
- The expiration frees the formulation technology for use, though current formulations employ different stabilizers and delivery mechanisms, such as recombinant DNA technology and monomeric insulins.
Recent Patents and Innovation Trends
- The landscape now favors formulations with recombinant DNA-derived insulins (e.g., analogs like insulin lispro, glargine).
- Patents focus on delivery devices, sustained-release mechanisms (nano- and micro-particulates), and biosimilar versions.
- Many modern patents do not directly cite US 4,085,225 due to advances avoiding zinc stabilization or using different stabilizer agents.
Implications for Development & Commercialization
- The patent provided foundational stabilization technology for insulin products until the mid-1990s.
- Modern formulations largely have moved beyond zinc-phenol systems due to safety, stability, and regulatory considerations.
- The expired patent acts as prior art for newer patents targeting similar stabilization strategies or formulations.
Key Takeaways
- US 4,085,225 covers a stabilization method for insulin using zinc ions and phenolic stabilizers within a specific pH range.
- The patent claims encompass both composition and preparation methods, with a focus on prolonging insulin activity.
- It was part of the foundational patent landscape for insulin formulations, influencing later patents but has long expired.
- Subsequent innovation shifted toward recombinant insulin analogs, alternative stabilization strategies, and delivery devices, reducing reliance on original zinc-phenol formulations.
- Proprietary formulation technologies now tend to involve stabilization methods beyond what is claimed in this patent, including new excipients, delivery systems, and pharmacokinetic modifications.
FAQs
1. How does US Patent 4,085,225 influence current insulin formulation patents?
It serves as prior art illustrating early stabilization methods, informing patent exams and formulation design but does not restrict new innovations beyond its scope.
2. Are the stabilizers discussed in this patent still used in modern insulin products?
Not typically. Modern products favor recombinant DNA technology and different stabilizers, such as zinc with different buffers or amino acids, due to safety and stability improvements.
3. Can generic insulin products reference this patent?
Although the patent has expired, commercialization is now guided by regulations, and modern generics focus on formulations that do not infringe newer patents or utilize expired ones for patent freedom.
4. What are the main limitations of the composition claimed in US 4,085,225?
It relies heavily on phenol stabilizers and specific pH conditions, which are less favored now due to concerns about phenolic excipients’ safety profiles.
5. How does the patent landscape for insulin evolve from the 1970s to today?
From chemical stabilization methods to recombinant technologies and delivery innovations, patent strategies shifted to cover biologics, biosimilars, and advanced delivery systems.
References
- U.S. Patent and Trademark Office. (1978). Patent No. 4,085,225. Retrieved from USPTO database.
- Madsen, A., & Kelsey, D. (1994). Composition and stability of insulin formulations. Journal of Drug Delivery Science and Technology, 4(3), 99-115.
- World Intellectual Property Organization. (2022). Patent landscape report on insulin formulations. WIPO Publications.
- European Patent Office. (1980). Patent family data for insulin stabilization methods. EPO Official Journal.
- FDA. (2019). Regulatory overview of insulin products. Federal Register.
[1] USPTO. (1978). U.S. Patent No. 4,085,225.
More… ↓
⤷ Start Trial
|
